We reported previously that adenocarcinoma-reactive human monoclonal antibody AE6F4, which had been generated by in vitro immunization method, recognizes both 14-3-3 protein and cytokeratin 8 (CK8). In this study, to analyze the cross-reactivity of AE6F4 antibody, epitopes of AE6F4 antibody on 14-3-3 proteins and CK8 were studied by using synthetic linear peptide scanning technology. To determine the locations of B cell epitope, 48 and 95 of decapeptides covering the entire 14-3-3 proteins and CK8, respectively, were synthesized and binding to AE6F4 antibody was examined by ELISA. The AE6F4 antibody was strongly reactive to peptides containing amino acid sequences TLWTSDTQGD in 14-3-3 proteins and INFLRQLYEE in CK8. These results indicate that AE6F4 antibody can recognize the different peptide sequences in 14-3-3 proteins and CK8.
Introduction
The human monoclonal antibody AE6F4 is secreted by a human-human hybridoma line established from the in vitro immunization of normal human peripheral blood lymphocytes with the human lung adenocarcinoma cell line, A549 (Kawahara et al., 1992) . This antibody is strongly reactive to lung cancer tissues (Shoji et al., 1994a) . Shoji et al. revealed that the AE6F4 antibody recognizes a 31 kDa antigen in the cytosolic fraction of A549 cells and partial amino acid sequence of this 31 kDa antigen shows a 90% homology to the 14-3-3 protein family (Shoji et al., 1994b) . Kawamoto et al. reported that the 31 kDa antigen cDNA cloned from A549 cells is identical to cytosolic phospholipase A2 (cPLA2) which is a member of the 14-3-3 protein family (Kawamoto et al., 1995) .
In our previous report, we purified two new kinds of antigens (53 kDa and 40 kDa), which were neither related to 14-3-3 proteins nor 31 kDa cPLA2, in human breast adenocarcinoma cell line, MCF-7 and identified that they were cytokeratin 8 and 19 (Ichikawa et al., 1997) . These data suggested that AE6F4 antibody cross-reactive to 14-3-3 proteins, CK8 and CK19. Our previous results of immunoblotting analysis with AE6F4 antibody against sodium periodate treated antigens suggested that AE6F4 antibody reacts with both carbohydrate part of 14-3-3 proteins and peptide epitopes on CK8 and CK19 (Kawamoto et al., 1995; Ichikawa et al., 1997 ). An accumulation of knowledge about the cross-reactivity of AE6F4 antibody is necessary in order to apply to diagnoses and medical treatments. A step toward understanding its cross-reactivity would be to determine the epitopes in antigens recognized by AE6F4 antibody. The present report therefore aims at presenting basic data on identification of epitopes recognized by AE6F4 antibody with the multi-pin synthetic peptide approach.
Materials and methods

Cells and cell culture
Human breast adenocarcinoma cell line, MCF-7 was cultured in ERDF medium supplemented with 10% fetal bovine serum (FBS) in a humidified atmosphere of 5% CO 2 /95% air. AE6F4 antibody producing hybridomas were also cultured under the above condition.
Antibody
Culture supernatant of hybridomas containing AE6F4 antibody was used in Western blot and peptide mapping. Concentration of AE6F4 antibody was measured by a sandwich enzyme-linked immunosorbent assay (ELISA) and adjusted to 1 µg ml −1 with culture medium.
Western immunoblot
MCF-7 cell extract preparation and immunoblot analysis was performed as described previously (Ichikawa et al., 1997) . Carbohydrates were cleaved by mild periodate oxidation at an acid pH, according to the method of Woodward et al. (1985) . Horseradish peroxidaseconjugated goat anti-human IgM antibody (1:1000 dilution with Block Ace; Dainippon Pharmaceuticals, Japan) was used for detection.
Peptide synthesis and epitope scanning
A total of 48 and 95 decapeptides covering the entire amino acid sequences of 14-3-3 proteins and CK8, respectively, were synthesized using an epitopeScanning Kit (Chiron Mimotopes, Australia) according to the manufacturer's instructions based on Fmoc chemistry. Peptides were designed to overlap by five amino acid residues in entire molecules (Tables 1 and  2 ). The success of the synthesis was monitored by simultaneous synthesis of a positive (PLAQ) and a negative (GLAQ) control peptide and by subsequently testing their binding to the supplied monoclonal antibody. The synthesized peptides, coupled to the surface of the polypropylene pins configured to a 96-well microtiter plate, were tested for binding with AE6F4 antibody using a modified ELISA. The pins were precoated for 1 hr in a microtiter plate containing 2% bovine serum albumin (BSA) and 0.1% Tween 20 in PBS (PBS-T). After the pre-coating, the pins were incubated overnight at 4 • C in AE6F4 conditioned medium (1 µg ml −1 IgM). They were then washed four times with PBS-T and incubated for 1 hr with alkaline phosphatase-conjugated goat anti-human IgM (1:2000 dilution with Block Ace). After four washes with PBS-T, the pins were placed in the wells of microtiter plate containing a p-nitrophenylphosphate substrate solution and color development was allowed to proceed for approximately 30 min at 37 • C.
Results
Reactivity of AE6F4 antibody to MCF-7 cell extract
In order to demonstrate the cross-reactivity of AE6F4 antibody, MCF-7 cell extracts were subjected to Western blotting analysis. As shown in Figure 1 , the 31 kDa antigen in the soluble fraction, 53 and 40 kDa antigens in insoluble fraction were detected by AE6F4 antibody. These antigens were previously reported 14-3-3 proteins (Shoji et al., 1994a; Kawamoto et al., 1995) , CK8 and CK19 (Ichikawa et al., 1997) , respectively. To confirm whether carbohydrate chains in these antigens participate in antigen recognition by AE6F4 antibody, the protein-transferred nitrocellulose membrane was treated with sodium periodate to destruct the carbohydrate chain structure. Reactivity of AE6F4 antibody with the 31 kDa antigen (14-3-3 proteins) was completely abolished (Figure 1 ), suggesting that carbohydrate chains play a crucial role in antigen recognition by AE6F4 antibody.
Mapping of epitopes with overlapping decapeptides of 14-3-3 proteins
Overlapping decapeptides, starting at every fifth amino acid and covering the entire 245 amino acids (aa) of human 14-3-3 proteins were synthesized on 48 pins (Table 1) . ELISA was performed with AE6F4 antibody. AE6F4 reacted strongly with peptides TL-WTSDTQGD (aa 226 to 235, pin 46) (Figure 2 ).
Mapping of epitopes with overlapping decapeptides of CK8
Overlapping decapeptides, starting at every fifth amino acid and covering the entire 483 amino acids (aa) of human CK8 were synthesized on 95 pins (Table 2) . ELISA was performed with AE6F4 antibody. AE6F4 reacted strongly with peptides IN-FLRQLYEE (aa 221 to 230, pin 45) and moderately with GLTDEINFLR (aa 216 to 225, pin 44), QYEDI-ANRSR (aa 266 to 275, pin 54) and LREYQELMNV (aa 371 to 380, pin 75) (Figure 3) . Pins 44 and 45 were 
Discussion
Our previous study suggested that the recognition of 14-3-3 proteins by AE6F4 antibody was affected by carbohydrate chains on 14-3-3 proteins (Kawamoto et al., 1995; Ichikawa et al., 1997) . However, it was not clear, because of insufficient data, whether its epitope was carbohydrate chain or peptides. In this study, we adopted the multi-pin synthetic peptide approach to clarify whether the antigen recognition of AE6F4 antibody is affected by carbohydrate chain or not. The result of immunoblot analysis implied that AE6F4 antibody reacted with carbohydrate chains but not with protein moiety of 14-3-3 glycoproteins. However, the result of epitope mapping with multi-pin synthetic peptides system revealed that AE6F4 antibody reacted with peptide of 14-3-3 proteins (aa 226 to 235, pin 46). These results suggested that AE6F4 antibody could bind to the 14-3-3 protein derived peptide without assistance of carbohydrate chain. We think a possibility that the other region in the same 14-3-3 molecules may mask AE6F4 binding epitope when carbohydrate chains are removed from the molecule. Carbohydrate chains added on 14-3-3 proteins may play an important role in baring AE6F4 binding epitope on 14-3-3 whole molecules. In the case of synthetic pin peptides, we may not make allowance for such an obstruction by the other region of 14-3-3 molecules. Homology between epitopes in 14-3-3 and CK8 identified by multi-pin synthetic peptide system was considerably low, contrary to expectation. Because AE6F4 antibody was generated by in vitro immunization method, affinity maturation of antibody accompanied with somatic hyper mutation did not occur. Indeed, variable regions of heavy and light chains of AE6F4 antibody were completely identical to germ line sequences, respectively (data not shown). Therefore the cause of the low homology among these epitopes is seemed to be the low specificity of AE6F4 antibody. In other words, AE6F4 antibody recognizes different epitopes between 14-3-3 proteins and CK8. Fortunately, 14-3-3 protein, CK8 and CK19 recognized by AE6F4 antibody were all closely related with cancer. Expressions of 14-3-3 proteins were significantly elevated in several cancer cells and tissues (Shoji et al., 1994b; Nakanishi et al., 1997; Villaret et al., 2000) . CK8 and CK19 are also known as the tumor marker proteins (Stieber et al., 1993; Xu et al., 1995) . Therefore 14-3-3 proteins, CK8 and CK19 may act synergistically in the cancer cell recognition of AE6F4 antibody. In the same way, these evidences ensure the validity of adenocarcinoma specific reaction of AE6F4 antibody.
The results of the epitope mapping indicated that AE6F4 antibody was reactive to different epitopes among 14-3-3 proteins and CK8. Because of lack of affinity maturation process accompanied by somatic hyper mutation, acquisition of human monoclonal antibody with high specificity and affinity would be difficult by in vitro immunization method. However, if effective antigen stimulation and cloning are carried out, a useful human monoclonal antibody with considerable affinity and specificity, like AE6F4 antibody, would be obtained by in vitro immunization method. Therefore in vitro immunization method will be able to be the one of the choice of the way for the acquisition of human monoclonal antibody, as well as humanization of mouse monoclonal antibody. For more application of in vitro immunization, it is expected to develop the effective procedure for affinity maturation of antibody in vitro.
